Company · TPST
Tempest Therapeutics, Inc.
Nasdaq's symbol directory lists TPST on Nasdaq as “Tempest Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($500K); 8 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Matthew Angel, CEO and President bought $500K
Every trade (1)
- BUYMatthew Angel, CEO and President bought $500K
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Notice of delisting or failure to meet a listing standard Nov 6, 2026
- Departure or appointment of directors or officers Oct 30, 2026
- Submission of matters to a vote of security holders; Other events Oct 20, 2026
- Departure or appointment of directors or officers; Regulation FD disclosure Oct 19, 2026
- Entry into a material definitive agreement; Departure or appointment of directors or officers; Regulation FD disclosure Sep 28, 2026
- Entry into a material definitive agreement; Regulation FD disclosure Sep 17, 2026
- Submission of matters to a vote of security holders; Other events Sep 16, 2026
- Entry into a material definitive agreement; Unregistered sales of equity securities Sep 15, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.